Charité Universitätsmedizin Berlin

Running trials

• Not yet recruiting

  CD19-B Cell Depletion in PAIS-ME/CFS Patients

  NCT07724834· Phase 2· Source

• Not yet recruiting

  DETECTRA: Remote Monitoring to Detect Rheumatoid Arthritis Flares and Treatment Response

  NCT07857993· Source

• Not yet recruiting

  Post-acute Infectious Syndrome - Aripiprazole Symptom Evaluation (PAIS-AriSE)

  NCT07714213· Phase 2· Source

• Not yet recruiting

  A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events

  NCT07474649· Phase 3· Source

• Not yet recruiting

  Pix-Risk: Early Detection of Rheumatoid Arthritis Via the DETECTRA Platform

  NCT07825233· Source

• Recruiting

  Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD

  NCT07010302· Phase 4· Source

• Recruiting

  Clinical Study on High-fiber Diet and Short-term Fasting in Melanoma Under Immunotherapy With Checkpoint Inhibition

  NCT07680452· Source

• Recruiting

  Registry for Duchenne and Becker Muscular Dystrophy

  NCT07402122· Source

• Recruiting

  A Study of TAK-755 in Adults With Acute Ischemic Stroke

  NCT07392450· Phase 2· Source

• Recruiting

  Safety and Antiviral Activity of a Monoclonal Hepatitis B Antibody: a Phase 1b, Open-label Trial in Individuals With Chronic Hepatitis D Infection

  NCT07610772· Phase 1· Source

• Recruiting

  MB-CART2019.1 in Refractory Multiple Sclerosis

  NCT07178431· Phase 1/2· Source

• Recruiting

  A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients

  NCT07549321· Phase 2/3· Source

• Recruiting

  Observational Study on Immunoadsorption (IA) in Patients With Autoantibody-Positive Post-Infectious ME/CFS

  NCT07529197· Source

• Recruiting

  Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders

  NCT07395206· Source

• Recruiting

  ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

  NCT07294170· Source

• Recruiting

  Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia

  2025-520982-39-00· Phase 3· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Source

• Enrolling by invitation

  Clinical Impact Through AI-assisted MS Care - A Prospective Multi-center Study

  NCT07032246· Source

• Recruiting

  #AWARE.HIV Europe: Supporting Healthcare Professionals to Find Undiagnosed HIV in European Hospitals: An Effectiveness-implementation Trial.

  NCT06900829· Source

• Recruiting

  Intensive Care Unit-acquired Heart Failure in Critically Ill: the ICU-HF Study

  NCT07094425· Source

• Recruiting

  Evaluation of Needs of Patients and Care-givers During and After Radiotherapy of Patients With Prostate Cancer

  NCT07156903· Source

• Recruiting

  Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC

  NCT07145450· Phase 1/2· Source

• Recruiting

  Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

  NCT06801834· Phase 3· Source

• Recruiting

  LEOPARD Training and Validation Data Collection Study

  NCT06675604· Source

• Recruiting

  A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

  NCT06585774· Phase 3· Source

• Recruiting

  Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

  NCT06472245· Phase 3· Source

• Active, not recruiting

  A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment

  NCT06447168· Source

• Active, not recruiting

  Predicting Cognition After DBS for Parkinson's Disease 2

  NCT06272968· Source

• Active, not recruiting

  Ultra-high-caloric, Fatty Diet in ALS

  NCT06280079· Source

• Recruiting

  Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic Fibrosis

  NCT06429176· Phase 2· Source

• Recruiting

  Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy

  NCT05976685· Source

• Recruiting

  Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

  NCT05485961· Phase 2/3· Source

• Recruiting

  Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients

  NCT06279793· Phase 2· Source

• Recruiting

  Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine

  NCT07159750· Source

• Recruiting

  Functional Imaging to Identify Radiosensitive Esophageal Cancer - a Biomarker Validation Study

  NCT06189898· Source

• Recruiting

  Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With TAS-102 (Lonsurf) and Bevacizumab in Refractory Metastatic Colorectal Cancer

  NCT05991102· Source

• Recruiting

  The Fourth Left Atrial Appendage Occlusion Study

  NCT05963698· Source

• Recruiting

  Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With Radiochemotherapy and Maintenance Chemotherapy in Patients With Glioblastoma (Brain-RF)

  NCT06140875· Source

• Recruiting

  ToFAcitinib in Early Active Axial SpondyloarThritis:

  NCT06112665· Phase 4· Source

• Active, not recruiting

  The BD Liverty™ TIPS Stent Graft Study

  NCT05711316· Source

• Recruiting

  TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study

  NCT05538806· Source

• Active, not recruiting

  A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology

  NCT06625203· Source

• Recruiting

  German Dementia Registry

  NCT07433010· Source

• Active, not recruiting

  TRICuspid Intervention in Heart Failure Trial

  NCT04634266· Source

• Active, not recruiting

  COMBINE-INTERVENE: COMBINEd Ischemia and Vulnerable Plaque Percutaneous INTERVENtion to Reduce Cardiovascular Events

  NCT05333068· Source

• Active, not recruiting

  A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung

  NCT05470595· Phase 2· Source

• Active, not recruiting

  A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

  NCT05070858· Phase 3· Source

• Active, not recruiting

  Prognostic Role of Circulating Tumor DNA in Resectable Pancreatic Cancer

  NCT04246203· Source

• Active, not recruiting

  EnDovascular Therapy Plus Best Medical Treatment (BMT) Versus BMT Alone for MedIum VeSsel Occlusion sTroke

  NCT05029414· Source

• Active, not recruiting

  Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease

  NCT05043103· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atrial fibrillation3 recruiting
• Childhood cancers3 recruiting
• Long COVID and ME/CFS3 recruiting
• Lung cancer3 recruiting
• Multiple sclerosis3 recruiting
• Stroke3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Ankylosing spondylitis2 recruiting
• Coronary artery disease2 recruiting
• Cystic fibrosis2 recruiting
• HIV2 recruiting
• Neuroblastoma2 recruiting
• Rheumatoid arthritis2 recruiting
• Schizophrenia2 recruiting
• Alzheimer disease1 recruiting
• Chronic kidney disease1 recruiting
• Colorectal cancer1 recruiting
• Crohn's disease1 recruiting
• Duchenne muscular dystrophy1 recruiting
• Epilepsy1 recruiting
• Familial hypercholesterolaemia1 recruiting
• Gastric and esophageal cancer1 recruiting
• Glioblastoma1 recruiting
• Head and neck cancer1 recruiting
• Heart failure1 recruiting
• Hepatitis B1 recruiting
• Melanoma1 recruiting
• Mesothelioma1 recruiting
• Migraine1 recruiting
• Myasthenia gravis1 recruiting
• Neuromyelitis optica (NMOSD)1 recruiting
• Primary biliary cholangitis1 recruiting
• Prostate cancer1 recruiting
• Psoriatic arthritis1 recruiting
• Sarcoma1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Clinical Trial to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Adults With CF

  NCT06468527· Phase 2· Source

• Completed

  Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.

  NCT05962606· Phase 2· Source

• Terminated

  IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack

  NCT06139328· Phase 2· Source

• Completed

  The "CAD-Man" EXTEND Study

  NCT06237673· Source

• Completed

  Immunoadsorption in Patients With Chronic Fatigue Syndrome Including Patients With Post-COVID-19 CFS

  NCT05710770· Source

• Terminated

  Methylprednisolone in Patients With Cognitive Deficits in Post-COVID-19 Syndrome (PCS)

  NCT05986422· Phase 2· Source

• Completed

  Hyperbaric High Pressure Oxygen Therapy in Post-COVID Syndrome and ME/CFS

  NCT06118138· Source

• Completed

  To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID

  NCT05911009· Phase 2· Source

• Completed

  Computer-assisted Risk Evaluation in the Early Detection of Psychotic Disorders

  NCT05813080· Source

• Terminated

  A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease

  NCT05744401· Phase 2· Source

• Completed

  A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis

  NCT05656911· Phase 2· Source

• Completed

  A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).

  NCT05578872· Phase 1/2· Source

• Completed

  Repeat Immunoadsorption Post Covid ME/CFS

  NCT05629988· Source

• Completed

  Efficacy and Safety on SOM3355 in Huntington's Disease Chorea

  NCT05475483· Phase 2· Source

• Completed

  New Prospective Expanded German Registry of Incidental Gallbladder Carcinoma (PERSUASION)- a Permanent Platform Including All Kind of Biliary Tract Cancers (BTC)

  NCT04896931· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Source

• Completed

  EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway

  NCT05093634· Phase 3· Source

• Completed

  DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway

  NCT04963231· Phase 2· Source

• Terminated

  Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

  NCT04968184· Phase 3· Source

• Terminated

  Open-Label Surufatinib in European Patients With NET

  NCT04579679· Phase 2· Source

• Terminated

  Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

  NCT04796324· Phase 2· Source

• Completed

  EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

  NCT04509674· Phase 3· Source

• Completed

  Fissure Closure With the AeriSeal System for CONVERTing Collateral Ventilation Status (CONVERT)

  NCT04559464· Source

• Completed

  PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)

  NCT04484636· Source

• Completed

  Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")

  NCT04474678· Source

• Completed

  Prevalence and Prognostic Relevance of Tricuspid Regurgitation in Different Heart Failure Entities

  NCT04570098· Source

• Completed

  A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD

  NCT04498650· Phase 2· Source

• Terminated

  Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)

  NCT03891576· Phase 2· Source

• Completed

  CIRSE Emprint Microwave Ablation Registry

  NCT03775980· Source

• Completed

  Atezolizumab Trial in Endometrial Cancer - AtTEnd

  NCT03603184· Phase 3· Source

• Completed

  Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

  NCT03648489· Phase 2· Source

• Completed

  Long Term Extension Trial of Setmelanotide

  NCT03651765· Phase 2/3· Source

• Completed

  A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

  NCT03283085· Phase 3· Source

• Completed

  MIND: Artemis in the Removal of Intracerebral Hemorrhage

  NCT03342664· Source

• Completed

  A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)

  NCT03412773· Phase 3· Source

• Completed

  A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors

  NCT03267316· Phase 1/2· Source

• Completed

  Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy

  NCT03081143· Phase 2/3· Source

• Completed

  Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

  NCT02914535· Phase 3· Source

• Completed

  A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

  NCT02908672· Phase 3· Source

• Completed

  Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

  NCT02902029· Phase 2· Source

• Completed

  Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)

  NCT02500381· Phase 3· Source

• Completed

  Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

  NCT02467270· Phase 2· Source